CRISPR Therapeutics Sees Commercial Ramp Driving Valuation
Seeking Alpha published April 1, 2026, rates CRISPR Therapeutics (CRSP) Buy with a 12-month price target of $64.58, citing CASGEVY's commercial ramp and rising patient initiations. The note highlights CRSP's in vivo cardiovascular pipeline — CTX310 and CTX320/321 — targeting large underserved markets, and roughly $2.5 billion cash supporting disciplined capital management. Analyst frames CASGEVY revenue as a near-term path to profitability.
Scoring Rationale
Fresh investment note provides directly usable guidance (price target, buy rating) and cites meaningful cash and pipeline metrics, raising actionability. Score lowered by single-source analyst opinion, limited novelty, and narrow company focus rather than industry-wide impact.
Practice with real Telecom & ISP data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Telecom & ISP problemsStep-by-step roadmaps from zero to job-ready — curated courses, salary data, and the exact learning order that gets you hired.
Sources
- Read OriginalA Turning Point For Crispr Therapeutics As Commercial Growth Accelerates (NASDAQ:CRSP)seekingalpha.com
